AL
RAPT

Aspiriant LLC’s RAPT Therapeutics RAPT Stock Holding History

Aspiriant LLC’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,250
Closed -$290K – 220
2020
Q2 		$290K Hold
1,250
– – 0.03% 157
2020
Q1 		$213K Buy
+1,250
New +$285K 0.02% 173

Other funds holding RAPT

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Aspiriant LLC's RAPT Position: Q3 2020 in Review

Aspiriant LLC sold out of RAPT Therapeutics (RAPT) in Q3 2020, closing a stake of 1,250 shares — an estimated $290K sold.

Aspiriant LLC first reported a position in RAPT in Q1 2020 and held it in 2 quarters. The position peaked at $290K in Q2 2020. 67 funds tracked by Wall St. Rank hold RAPT as of Q3 2020.

  • Aspiriant LLC reported no remaining RAPT Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Aspiriant LLC sold 1,250 RAPT Therapeutics shares in Q3 2020, an estimated $290K.
  • Aspiriant LLC first reported a position in RAPT Therapeutics in Q1 2020 and held it in 2 quarters.
  • Aspiriant LLC's RAPT Therapeutics position peaked at $290K in Q2 2020.
  • 67 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2020.

Based on Aspiriant LLC's 13F filing for Q3 2020, filed 29 Oct 2020.